He served in Israeli intelligence, earned a Ph.D. in biochemistry, won a Fulbright to Stanford, graduated from Singularity University, built and sold a synthetic biology startup, ran corporate development at a NASDAQ-listed company, launched his own pre-seed fund, joined a $1.4 billion venture firm, and co-founded the most controversial biotech company of 2022 - all before you finished reading this sentence.
This is not a career path. It is a controlled detonation.
Omri Amirav-Drory is the General Partner of NFX Bio, the life sciences arm of NFX - the Silicon Valley firm with $1.4 billion under management and a singular obsession with network effects. He is also, simultaneously, the co-founder and chairman of Renewal Bio, a company quietly sitting on what he calls "the most potential I've seen since CRISPR first emerged." The company does not advertise. Its founders do not do press tours. When MIT Technology Review published their story in August 2022, the headline was, essentially: this is going to be controversial. Drory's response to the reporter was careful, measured, and revealing: "We don't want to overpromise, and we don't want to freak people out."
That tension - between ambition so vast it requires constant understatement, and the discipline to keep it from getting ahead of the science - is the engine of Omri Drory.
Biology is the most advanced technology on earth. And there is something even more advanced than biology: Entrepreneurship.
- Omri Amirav-Drory, NFX BioThe Biochemist Who Learned to Ship Code
It started in a Tel Aviv University lab. A biochemistry degree in 2003, then a Ph.D. four years later, then - this is the part most scientists don't do - he left. Not for industry. Not for consulting. He won a Fulbright Scholarship and landed in the lab of Axel Brunger at Stanford: protein structure, molecular machines, the architecture of life at resolution too small to see.
He graduated from Singularity University in 2011. The same year, he co-founded Genome Compiler. The idea was deceptively simple: CAD software for DNA. Just as AutoCAD let engineers design buildings without drafting by hand, Genome Compiler let synthetic biologists design genetic constructs without wrestling with sequence data in spreadsheets. It was "GitHub for DNA" before that phrase existed.
In April 2016, Twist Bioscience acquired Genome Compiler. Twist IPO'd on NASDAQ. Its peak market cap touched $2.5 billion. Drory stayed on as VP of Corporate Development & Innovation - the unusual position of being the acquired founder who outlasts the transaction and shapes what comes next.
"Founders can imagine the world as it should be. They can rip a hole in this universe and take us to a new one - and then build it."
From Acquiree to VC: The Tech.bio Detour
He left Twist in 2018 and did something unusual for a scientist: he launched a pre-seed venture fund. Tech.bio was early, small, and pointed - a fund investing in the gap between academic research and institutional biotech, the moment when a scientist has a platform but no playbook.
The bets from that period tell the story. Mammoth Biosciences - CRISPR diagnostics, Series A when it was still a PowerPoint premise, eventually a unicorn. C2i Genomics - liquid biopsy cancer intelligence, later acquired. He had a thesis before he had a fund name for it: TechBio. Not biotech. TechBio. The distinction matters to him enormously.
Traditional biotech, in his framing, is a one-drug bet: you discover a molecule, run trials, pray. TechBio is a platform play: you discover a biology, then use it to solve ten problems instead of one. The economics are different. The defensibility is different. The founder profile is different.
The harder a problem is to solve, the more certain you should be that it's worth solving. That's a major reason bio is about to dominate the next decade of innovation.
- Omri Amirav-DroryNFX Bio: A Home for Scientists Who Code
In 2020, Drory joined NFX as a General Partner to formalize that thesis at scale. NFX was already known for its network-effects research and its early bets in consumer and marketplace companies. Adding a dedicated bio vertical with a scientist-operator-investor as its leader was a statement about what the next decade of venture would look like.
NFX Bio invests at pre-seed and seed - checks of $500K to $5M, with a sweet spot around $3M. Drory leads or co-leads. He sits on boards. He helps scientists become founders, which he insists is easier than most people think and harder than most founders admit.
His framework for evaluating companies is not complicated: Is the solution big enough? Does the team have "defensible magic" - scientific insight that cannot be easily replicated? Are these the right people? And then, the question that doesn't appear on any investment memo: Do they think about it day and night? Do they have the passion to survive the inevitable?
He has published more than 44 essays on the NFX platform. Not ghostwritten, not summarized from talks - actual thinking, published. Topics range from "Why Great Bioplatforms Will Always Win" to "The Last Problem for AI to Solve is Health" (published in early 2026). He gives new VCs a specific piece of advice that sounds counterintuitive until you sit with it: "Don't invest for the first 9 months. Build pattern recognition by seeing many companies." He presumably followed his own counsel.
Renewal Bio: When "Don't Freak People Out" Is a Strategy
In May 2022, Drory co-founded Renewal Bio with Professor Jacob Hanna of the Weizmann Institute. Hanna had done something remarkable: his lab had created synthetic embryo models from stem cells - structures that developed their own heartbeats, neural tubes, blood cells, without a sperm or egg. The models were "real enough" to study development but could never become a baby (they lack the supporting cells for implantation).
Renewal Bio secured an exclusive license from Yeda R&D, Weizmann's tech transfer arm, for Hanna's platform. The applications Drory describes: treating infertility, correcting genetic diseases before birth, growing organs and tissues for transplant, rejuvenating the blood system. These are not incremental improvements. These are the things that, before 2022, you could only do in science fiction.
The comparison he keeps returning to is CRISPR. Not because the technologies are similar, but because they share a property: once you see what it can do, the universe of applications is so large that the first instinct is disbelief. "I haven't seen a technology with so much potential since CRISPR gene-editing technology first emerged," he has said. And then, aware of the silence that follows: "We don't want to overpromise, and we don't want to freak people out."
I would rather have a mediocre technology with an incredible team, than incredible tech with mediocre team.
- Omri Amirav-DroryThe Race to 160: A Thesis as Personal as It Is Professional
Drory's investment thesis has a name: The Race to 160. The number is not a marketing stunt. It is a claim about what becomes possible when you treat aging as a solvable systems problem rather than an inevitable biological fate. Aging, in his framework, is the root cause of nine out of ten leading causes of human death. Fix aging and you have addressed - not cured, but addressed - most of the things that kill people who don't want to be killed.
He has developed what he calls an ABCD framework for thinking about aging across four dimensions. He does not publish the details; it lives in his talks and podcasts for those curious enough to find it. What is public is the orientation: this is not recreational futurism. This is a man with a biochemistry doctorate, a working understanding of protein structure from one of the world's best structural biology labs, and an operator's instinct for which problems have traction.
Reading science fiction, he says, helps him "envision a world different and better than the one I'm living in." He is on the advisory board of the Lifeboat Foundation, a nonprofit focused on existential risk. He has three children. He is a proud husband. He is, by any reasonable measure, a person who has thought hard about what the world owes the next generation and has decided the answer involves aggressive intervention.
The Contrarian at the Center: Scientist-CEOs
There is one fight Drory picks consistently, in every interview, in every panel discussion, in the writing he publishes on NFX: the biotech industry's habit of replacing scientist-founders with professional managers.
The conventional wisdom in pharmaceutical and biotech venture runs roughly like this: scientists are good at discovering things; they are not good at running companies; therefore, hire a CEO from industry and keep the scientist in a Chief Scientific Officer box. Drory considers this a failure mode. Not a preference. A failure mode.
His argument: scientists who founded the company understand the science in a way that cannot be fully transferred. They have the domain knowledge, the network in the research community, and - crucially - the motivation that comes from having built the insight themselves. When the data is ambiguous, when the board wants to pivot, when the investors want to rush a timeline, the scientist-founder is the person who knows whether the ambiguity is real or whether someone is being impatient. The MBA hire does not know this.
"Scientists make great founders because they care," he has written. "They have deep scientific knowledge, and their experience in the lab proves grit." He has also said he is committed to a future where "scientist-CEO is the norm, not the exception."
NFX Bio is built around this belief. Every company he backs is built around this belief.
What Comes Next
In 2026, Drory is speaking at SynBioBeta, writing for the NFX platform, sitting on boards at Cyclana Bio, Permanence Bio, Powerhouse Biology, ImmuneBridge, and Pangea Biomed, running NFX Bio's investment operations, and chairing Renewal Bio. He is, by most definitions, doing too much. By his own logic, he is doing exactly enough.
He gives new investors a piece of advice that works equally well for founders: "If you're courageous enough to ask for help, most people are willing to give it." The corollary, which he does not state but which his career implies: you have to be doing something worth asking about.